Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels

Stage IV metastatic melanoma patients historically have a poor prognosis with 5–10% 5-year survival. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA4), is one of the first treatments to provide beneficial durable responses in advanced melanoma. However, less than 25%...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Anna M., Lee, Agnes Fermin, Ozao-Choy, Junko, Ramos, Romela Irene, Hamid, Omid, O’Day, Steven J., Shin-Sim, Myung, Morton, Donald L., Faries, Mark B., Sieling, Peter A., Lee, Delphine J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032905/
https://www.ncbi.nlm.nih.gov/pubmed/24904825
http://dx.doi.org/10.3389/fonc.2014.00110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032905/
https://www.ncbi.nlm.nih.gov/pubmed/24904825
http://dx.doi.org/10.3389/fonc.2014.00110

Ejemplares similares